Functional scintigraphy of the adrenal gland

European Journal of Endocrinology

Volumn 147, Issue 1, 2002, Pages 13-28

  Rubello, Domenico ^a   Bui, Chuong ^a   Casara, Dario ^a   Gross, Milton D ^a   Fig, Lorraine M ^a   Shapiro, Brahm ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 6BETA IODOMETHYL 19 NORCHOLEST 5(10) EN 3BETA OL I 131; AMINO ACID; BOMBESIN; CATECHOLAMINE; CELL SURFACE RECEPTOR; CHOLESTEROL DERIVATIVE; CHOLESTEROL ESTER; CORTICOSTEROID; ENZYME INHIBITOR; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; METYRAPONE; NEUROTRANSMITTER; OCTREOTIDE[3 TYROSINE]; PENTETREOTIDE IN 111; PEPTIDE; RADIOISOTOPE; RECEPTOR SUBTYPE; SELENIUM 75; SOMATOSTATIN RECEPTOR; TRACER; TYROSINE; UNINDEXED DRUG;

ADRENAL CORTEX; ADRENAL CORTEX ADENOMA; ADRENAL CORTEX CELL; ADRENAL DISEASE; ADRENAL MEDULLA TUMOR; ADRENAL SCINTISCANNING; CATECHOLAMINE SYNTHESIS; CATECHOLAMINE UPTAKE; CHOLESTEROL SYNTHESIS; CLINICAL PRACTICE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DRUG DISTRIBUTION; FEMALE; GLYCOLYSIS; HUMAN; HUMAN CELL; ISOTOPE LABELING; MAJOR CLINICAL STUDY; MALE; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; REVIEW; SENSITIVITY AND SPECIFICITY; STEROIDOGENESIS; ZONA FASCICULATA; ZONA GLOMERULOSA;

EID: 0036319537     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1470013     Document Type: Review

References (89)

1. Adrenal imaging agents: Rationale, synthesis, formulation and metabolism
2. Tumor localizing agents. IX. Radioiodinated cholesterol
3. New adrenal-scanning agent
4. A new and superior adrenal scanning agent, NP-59
5. Imaging the adrenal glands with radiolabeled inhibitors of enzymes: Concise communication
6. PET imaging of adrenal cortical tumors with the 11beta-hydroxylase tracer 11C-metomidate
7. Nuclear imaging analysis of human low density lipoprotein biodistribution in rabbits and monkeys
8. Indeterminate adrenal mass in patients with cancer: Evaluation at PET with 2-F-18-fluoro-2-deoxy-D-glucose
9. The scintigraphic imaging of endocrine organs
10. Clinical experience with 75-Se-selenomethylcholesterol adrenal imaging
11. Adrenal glands
12. Enterohepatic circulation and distribution of I-131-iodomethyl-19-norcholesterol (NP-59)
13. Radiocholesterol diagnosis of adrenal disease
14. Radionuclide imaging of the adrenal cortex
15. Value of bowel preparation in adrenocortical scintigraphy with NP-59
16. Clinical application of SPECT in adrenal imaging with I-131-6β-iodomethyl-19-norcholesterol
17. The role of pharmacologic manipulation in adrenal cortical scintigraphy
18. Adrenal scintigraphy
19. The functional characterization of the adrenal gland by quantitative scintigraphy
20. The localization of abnormal adrenal function in ACTH-independent Cushing's syndrome
21. Adrenal scintigraphy of well-differentiated (functioning) adrenocortical carcinomas: Potential surgical pitfalls
22. Clinical significance of the solitary functioning adrenal gland
23. Iodomethylnorcholesterol uptake in an aldosteronoma shown by dexamethasone-suppression scintigraphy: Relationship to adenoma size and functional activity
24. Adrenocortical scintigraphy
25. The relationship of 131I-6β-iodomethyl-19-norcholesterol (NP-59) adrenal cortical uptake to indices of androgen secretion in women with hyperandrogenism
26. Clinical review 50: Clinically silent adrenal masses
27. Incidentally discovered adrenal masses
28. Incidentally discovered adrenal tumors: An institutional perspective
29. Non-functioning functioning adrenal masses: Incidental discovery on computed tomography
30. Differentiation of malignant from benign adrenal masses: Predictive indices on computed tomography
31. Adrenal cortical adenomas and hypertension. A clinical pathologic analysis of 690 cases with matched control and a review of the literature
32. Sensitivity and specificity of computed tomography for the detection of adrenal metastatic lesions among 91 autopsied lung cancer patients
33. Adrenal masses: Prevalence, significance, and management
34. Suprarenal mass and its differential diagnosis
35. Incidentalomas of the adrenal gland: 36 operated patients and review of literature
36. Clinical significance of the large adrenal mass
37. Differential diagnosis of solid adrenal masses using adrenocortical scintigraphy
38. Benign and malignant adrenal masses: CT distinction with attenuation coefficients, size, and observer analysis
39. Metastasis or adenoma? Computed tomography evaluation in the adrenal mass
40. Benign adrenocortical masses: Diagnosis with chemical shift MR images
41. Adenocarcinoma metastatic to the adrenal gland simulating myelolipoma: CT evaluation
42. Narrow gauge needle aspiration of solid adrenal masses
43. Distinguishing benign from malignant adrenal masses
44. Functional and scintigraphic evaluation of the silent adrenal mass
45. Evolving concepts in the pathophysiology, diagnosis, localization and treatment of pheochromocytoma
46. The diagnosis and therapeutic utility of the radioiodinated metaiodobenzylguanidine (MIBG). Five years' experience
47. Radioisotope diagnosis of malignant pheochromocytoma
48. 131-iodine-metaiodobenzylguanidine for the location of suspected pheochromocytoma: Experience in 400 cases
49. Adrenal hypertension
50. Metaiodobenzylguanidine and somatostatin in oncology: Role in the management of neural crest tumours
51. Labetalol reduces iodine-131 MIBG uptake by pheochromocytoma and normal tissue
52. Methodology and dosimetry in adrenal medullary imaging with iodine-131 MIBG
53. Comparison of iodobenzylguanidine imaging with computed tomography in locating pheochromocytoma
54. The normal and abnormal distribution of the adrenomedullary imaging agent I-131-metaiodobenzylguanidine (I-MIBG) in man: Evaluation by scintigraphy
55. Quantitation of iodine-123 MIBG uptake by normal adrenal medulla in hypertensive patients
56. Observations on the function of normal adreno-medullary tissue in patients with phaeochromocytomas and other paragangliomas
57. Uptake of iodine-123 MIBG by pheochromocytomas, paragangliomas, and neuroblastomas: A histopathological comparison
58. Radioiodinated MIBG for the diagnostic scintigraphy and internal radiotherapy of neuroendocrine tumors
59. Malignant pheochromocytoma: Clinical, biochemical and scintigraphic characterization
60. The spectrum of pheochromocytoma in hypertensive patients with neurofibromatosis
61. MIBG in the diagnosis of neural crest tumours
62. RET gene and its implications for cancer
63. New tracers for the imaging of the medullary thyroid carcinoma
64. 99mTc-MIBI scintigraphy: An effective imaging technique in detecting loco-regional metastases of medullary thyroid carcinoma
65. Somatostatin receptor scintigraphy with 111In-DTPA-D-Phe1-octreotide
66. Somatostatin receptor scintigraphy with 111In-DTPA-D-PHE1-octreotide in man: Metabolism, dosimetry and comparison with 123-Try-3-octreotide
67. Somatostatin receptor scintigraphy: Its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study
68. Indium-111-DTPA-octreotide uptake measured in normal and abnormal pituitary glands
69. Somatostatin analogue scintigraphy in carcinoid tumors
70. Preoperative detection of duodenal gastrinomas and peri-pancreatic lymph node by somatostatin receptor scintigraphy
71. In vivo somatostatin receptor imaging in medullary thyroid carcinoma
72. The applications of PET in clinical oncology
73. Targeting glucose transporters for tumor imaging: Sweet idea, sour result
74. Cervical lymph node sarcoidosis as a pitfall in F18 FDG positron emission tomography
75. Fluorine-18 fluorodeoxyglucose PET in infections bone diseases: Results of histologically confirmed cases
76. Influence of the blood glucose concentration of FDG uptake in cancer - A PET study
77. Fluorine-18 deoxyglucose and false-positive results: A major problem in the diagnosis of oncological patients
78. Detection of malignancies with SPECT versus PET, with 2-fluorine-18-2-deoxy-D-glucose
79. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: A study with positron emission tomography and fluorine-18-fluorodeoxyglucose
80. Potential role of fluorine-18-deoxyglucose (FDG) positron emission tomography (PET) in the staging of primitive and recurrent medullary thyroid carcinoma
81. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours
82. Neuroendocrine tumor imaging: Can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior?
83. High rate of unsuspected distant metastases by PET in apparent stage III non-small-cell cancer: Implication for radical radiation therapy
84. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography
85. Diagnostic scintigraphy in postoperative staging and follow-up of differentiated thyroid carcinoma
86. 18F-FDG whole body positron emission tomography (PET) in the detection of unknown primary tumors
87. Imaging of an adrenal cortex carcinoma and its metastasis with FDG-PET
88. Pheochromocytomas: Imaging with 2-fluorine-18-fluoro-2-deoxy-D-glucose PET
89. Imaging of adrenal tumors using FDG PET: Comparison of benign and malignant lesions